Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit

CompletedOBSERVATIONAL
Enrollment

5,000

Participants

Timeline

Start Date

April 2, 2020

Primary Completion Date

May 26, 2022

Study Completion Date

May 26, 2022

Conditions
Non Small Cell Lung Cancer
Interventions
DIAGNOSTIC_TEST

therascreen® KRAS RGQ PCR Kit

The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue.

Trial Locations (1)

M130BH

QIAGEN Gaithersburg, Inc, Manchester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

QIAGEN Gaithersburg, Inc

INDUSTRY